title: [Local fibrinolysis of hypertensive intracerebral hematomas].
abstract: Authors presented the results of experimental and clinical studies of effects of recombinant prourokinase on brain tissue, its toxicity and safety in intracerebral administration for lysis of hypertensive intracerebral hematomas. Experiments were performed in 64 rabbits. Histological specimens were examined in different periods after injection of prourokinase into white matter and into experimental hematoma. It is revealed that dose of 615 mg/kg causes minimal changes in cerebral tissue. Clinical study was based on analysis of puncture aspiration of intracerebral hematomas with local fibrinolysis performed in 275 patients with hemorrhagic stroke. Dynamics of MRI, clinical and laboratory parameters, coagulation, analysis of aspirated products of lysis were assessed. Authors showed that recombinant prourokinase and the drug "Puroplazan" are effective for local fibrinolysis. The drugs are non-toxic and non-allergenic and do not cause cerebral edema.
authors.forename: A S
authors.initials: AS
authors.lastname: Saribekian
authors.forename: E V
authors.initials: EV
authors.lastname: Arzamastsev
authors.forename: R Sh
authors.initials: RSh
authors.lastname: Bibilashvili
authors.forename: V L
authors.initials: VL
authors.lastname: Golubykh
authors.forename: A A
authors.initials: AA
authors.lastname: Belogurov
authors.forename: L N
authors.initials: LN
authors.lastname: Poliakova
authors.forename: V A
authors.initials: VA
authors.lastname: Ponomarev
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006406:Hematoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D006801:Humans; D020299:Intracranial Hemorrhage, Hypertensive / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D011859:Radiography; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013396:Suction; D015912:Thrombolytic Therapy / Q000379:methods*; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase